ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.
Sullivan I, Planchard D.
Ther Adv Med Oncol · review-article; review; journal article · DOI 10.1177/1758834015617355 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för alectinib hydrochloride. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
14 träffarAlectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer.
Okuma Y, Tanaka Y, Kamei T, Hosomi Y, Okamura T.
Onco Targets Ther · research-article; journal article · DOI 10.2147/ott.s83179Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, Chi AS, Shaw AT.
J Thorac Oncol · research-article; journal article; case reports; research support, n.i.h., extramural · DOI 10.1097/jto.0000000000000455Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer.
Koizumi T, Fukushima T, Tatai T, Kobayashi T, Sekiguchi N, Sakamoto A, Sasaki S.
Lung Cancer · journal article; case reports · DOI 10.1016/j.lungcan.2015.01.018Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib.
Ajimizu H, Kim YH, Mishima M.
Med Oncol · journal article; case reports · DOI 10.1007/s12032-014-0477-7Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
McKeage K.
Drugs · review; journal article · DOI 10.1007/s40265-014-0329-yActivated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
Kogita A, Togashi Y, Hayashi H, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K.
Int J Oncol · research support, non-u.s. gov't; journal article · DOI 10.3892/ijo.2014.2797Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
Ikeda S, Yoshioka H, Arita M, Sakai T, Sone N, Nishiyama A, Niwa T, Hotta M, Tanaka T, Ishida T.
Jpn J Clin Oncol · research support, non-u.s. gov't; journal article; case reports · DOI 10.1093/jjco/hyu183Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H.
Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-14-0274Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H.
Cancer Chemother Pharmacol · journal article · DOI 10.1007/s00280-014-2578-6Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
Kodama T, Tsukaguchi T, Yoshida M, Kondoh O, Sakamoto H.
Cancer Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.canlet.2014.05.020Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
Ignatius Ou SH, Azada M, Hsiang DJ, Herman JM, Kain TS, Siwak-Tapp C, Casey C, He J, Ali SM, Klempner SJ, Miller VA.
J Thorac Oncol · journal article; case reports · DOI 10.1097/jto.0000000000000094Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
Zdzalik D, Dymek B, Grygielewicz P, Gunerka P, Bujak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K.
J Cancer Res Clin Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s00432-014-1589-3CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, Oikawa N, Tsukuda T, Ishii N, Aoki Y.
Cancer Cell · journal article · DOI 10.1016/j.ccr.2011.04.004